Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will
disclose the target and present new preclinical data for XMT-2056,
its first Immunosynthen STING-agonist ADC candidate, in a plenary
session at the upcoming AACR-NCI-EORTC Virtual International
Conference on Molecular Targets and Cancer
Therapeutics.
Details of the presentation are as follows:
Plenary Session Title: Tumor-Targeted
Conjugates: A Growing FamilyPresentation Title:
XMT-2056: Tumor-targeted Innate Immune Activation via a
STING-agonist Antibody Drug ConjugateDate/Time:
Thursday, October 7, 2021 from 12:50 – 2:40 p.m.
ETPresenter: Timothy B. Lowinger, Ph.D., Chief
Science & Technology Officer, Mersana Therapeutics
A replay of the webcasted presentation will be
available on October 7th after 4 p.m. ET on the Investors &
Media section of the Mersana website
at www.mersana.com.About Mersana
TherapeuticsMersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is
being studied in UPLIFT, a single-arm registration strategy in
patients with platinum-resistant ovarian cancer, as well as in
UPGRADE, a Phase 1 umbrella study in combination with other ovarian
cancer therapies. UpRi is also being studied in the expansion
portion of a Phase 1 proof-of-concept clinical study. XMT-1592,
Mersana’s second ADC product candidate targeting NaPi2b-expressing
tumors, was created using Mersana’s customizable and homogeneous
Dolasynthen platform and is in the dose escalation portion of a
Phase 1 proof-of-concept clinical study. The Company’s early-stage
programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as
well as XMT-2056, a STING-agonist ADC developed using the Company’s
Immunosynthen platform. In addition, multiple partners are using
Mersana’s Dolaflexin platform to advance their ADC pipelines. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Contact:Investor & Media ContactSarah
Carmody617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024